A Agilent Technologies Inc.

Agilent’s ESG Report Highlights Expansion of Solutions to Help Labs Manage Their Environmental Footprint

Agilent Technologies Inc. (NYSE: A) today released the company’s , showcasing a comprehensive and growing set of sustainable solutions that enable hundreds of thousands of labs worldwide to reduce consumption of nonrenewable resources and to minimize waste.

This press release features multimedia. View the full release here:

Agilent's 2023 ESG Report (Graphic: Business Wire)

Agilent's 2023 ESG Report (Graphic: Business Wire)

Agilent’s sustainable solutions include the sector’s largest instrument recycling and refurbishment program and an expanding number of My Green Lab ACT-labeled products that account for 40% of the company’s instrument revenue. The company is also delivering asset monitoring technology to manage lab resources more efficiently and a wide variety of instruments and consumables that use less energy and produce less waste. The report also highlights Agilent’s accelerated progress in adopting greener product packaging.

“Our global leadership in the lab-instrument and technology sector enables us to have a positive impact on science and society—from supporting more effective cancer diagnosis and treatment to ensuring the food we eat and the water we drink are safe,” said Padraig McDonnell, Agilent president and CEO. “It also drives our efforts as a leading sustainable lab partner for our customers, a top workplace for diverse talent, and a responsible steward of the environment.”

Below are highlights from Agilent’s 2023 ESG initiatives:

Product Sustainability

  • Expanded the to more product families, increasing from 35% to 40% the share of instrument revenue from ACT-labeled instruments that provide customers information on the environmental footprint of Agilent products.
  • Refurbished 5,400 instruments, a 25% increase over the previous year, which reflects growing demand for the company’s circular economy initiative known as the Agilent
  • Earned the Scientists’ Choice 2023 Sustainable Product of the Year award for the Agilent Cary 3500 Flexible UV-Vis Spectrophotometer, which reduces the use of consumables and reagents.
  • Implemented more sustainable packaging for many products, including the GC1 Packed Column box, 5500a FTIR Flow Cell Stanhope instrument, and Easi portfolio, eliminating hundreds of pounds of foam and plastic waste annually. Replaced paper chemical standards labels with QR codes, saving 700,000 pieces of paper annually at a single facility.

Environmental

  • Reduced Scope 1 and 2 emissions by 8% since 2019, even as the company’s revenue grew more than 30% over the same period.
  • Received validation of the company’s net-zero emissions targets from the Science Based Targets initiative.
  • Held dozens of net-zero emissions forums and workshops with suppliers and assessed the carbon maturity of over 200 suppliers.
  • Eliminated up to 80,000 gallons of organic waste per year at the company’s oligonucleotide manufacturing facility through an innovative recycling system.

Workforce Diversity and Engagement

  • Achieved Great Place to Work® certification in 27 countries and territories and was named one of the best workplaces in Canada, China, France, Germany, Italy, Japan, Singapore, South Korea, Spain, Taiwan and the United Kingdom.
  • Earned high ratings from employees, with 89% of those surveyed indicating Agilent is a great place to work.
  • Recognized as a top employer for women by Forbes, and once again achieved gender-based pay equity.
  • Donated $1.5 million to Delaware State University, a historically Black university, and $175,000 to eight STEM education nonprofit organizations to expand opportunities for underrepresented students; accompanied donations with hundreds of hours of mentorship by employee volunteers.
  • Generated $4.3 million for a broad set of charities through employee donations and matching contributions from the Agilent Foundation. 

Agilent also invested $11 million in awards to support academic research that advances science and society in key areas, including bioprocess engineering, synthetic biology, quantitative analysis of pollutants like per- and polyfluoroalkyl substances (PFAS), and CAR-T cell manufacturing.

Read Agilent’s for details on these and many more environmental and social initiatives in 2023. Learn more about Agilent’s sustainability initiatives throughout the year at

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the . Follow Agilent on and .

EN
26/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch